Search

XC221

XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

BNC105

GlycoPEG-GCSF

GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

AMG-222

3-Acetylpyridine Adenine Dinucleotide

It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)

NOV-002

NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.

IDD-1

As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

NTLA-2002

It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]

mRNA-3927

mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid

9MW3011

The drug is an anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibody.[L54591, L54596]